Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable

In the middle of November, Editas Medicine (NASDAQ: EDIT) and Celgene (NASDAQ: CELG) announced changes to a development pact originally formed in 2015 with Juno Therapeutics, which is now part of Celgene. The agreement was amended in 2018, too, so the fact that changes were made wasn't necessarily big news. Editas received a $70 million upfront payment for executing the amended agreement, which was interpreted as the main takeaway from the announcement.